Search Results - "Neelakantham, Srikanth"

Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data by Schoedel, Kerri A., Kolly, Carine, Gardin, Anne, Neelakantham, Srikanth, Shakeri-Nejad, Kasra

“…Abuse and misuse of prescription drugs remains an ongoing concern in the USA and worldwide; thus, all centrally active new drugs must be assessed for abuse and…”
Get full text

Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes by Gardin, Anne, Shakeri-Nejad, Kasra, Feller, Andrea, Huth, Felix, Neelakantham, Srikanth, Dumitras, Swati

“…Purpose To evaluate the PK and safety of siponimod, a substrate of CYP2C9/3A4, in the presence or absence of a CYP3A4 inhibitor, itraconazole. Methods This was…”
Get full text

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous Siponimod: A Randomized, Open-label Study in Healthy Subjects by Shakeri-Nejad, Kasra, Gardin, Anne, Gray, Cathy, Neelakantham, Srikanth, Dumitras, Swati, Legangneux, Eric

“…The goal of this study was to assess the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of intravenous (IV) siponimod in healthy…”
Get full text

Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals by Garito, Tania, Roubenoff, Ronenn, Hompesch, Marcus, Morrow, Linda, Gomez, Katherine, Rooks, Daniel, Meyers, Charles, Buchsbaum, Monte S., Neelakantham, Srikanth, Swan, Therese, Filosa, Lee Anne, Laurent, Didier, Petricoul, Olivier, Zakaria, Marjorie

“…Aim To test the hypothesis that an improving body composition in insulin‐resistant individuals could enhance insulin sensitivity. Methods A total of 16 people…”
Get full text

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers by Badman, Michael K., Chen, Jin, Desai, Sachin, Vaidya, Soniya, Neelakantham, Srikanth, Zhang, Jie, Gan, Lu, Danis, Kate, Laffitte, Bryan, Klickstein, Lloyd B.

“…Tropifexor (LJN452) is a potent, orally available, non–bile acid farnesoid X receptor agonist under clinical development for chronic liver diseases. Here, we…”
Get full text

Safety, Tolerability and Pharmacodynamics of Intravenous Siponimod in Healthy Subjects (P3.399) by Shakeri-Nejad, Kasra, Gardin, Anne, Gray, Cathy, Neelakantham, Srikanth, Dumitras, Swati, Legangneux, Eric

“…Abstract only…”
Get full text

Absolute Bioavailability of Single, Oral Dose of Siponimod in Healthy Subjects (P3.402) by Gardin, Anne, Shakeri-Nejad, Kasra, Gray, Cathy, Neelakantham, Srikanth, Legangneux, Eric, Dumitras, Swati

“…Abstract only…”
Get full text

Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects by Gardin, Anne, Gray, Cathy, Neelakantham, Srikanth, Huth, Felix, Davidson, Antonia M., Dumitras, Swati, Legangneux, Eric, Shakeri-Nejad, Kasra

“…Purpose To assess the potential pharmacokinetic (PK) interactions between siponimod and rifampin, a strong CYP3A4/moderate CYP2C9 inducer, in healthy subjects…”
Get full text

Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study by Gardin, Anne, Dodman, Angela, Kalluri, Sampath, Neelakantham, Srikanth, Tan, Xuemei, Legangneux, Eric, Shakeri-Nejad, Kasra

“…To investigate the pharmacokinetics (PK), safety, and tolerability of siponimod and selected inactive metabolites (M3 and M5) in subjects with varying degrees…”
Get full text

Assessment of pharmacokinetic drug-drug interaction between pradigastat and atazanavir or probenecid by Mendonza, Anisha, Hanna, Imad, Meyers, Dan, Koo, Phillip, Neelakantham, Srikanth, Zhu, Bing, Majumdar, Tapan, Rebello, Sam, Sunkara, Gangadhar, Chen, Jin

“…Pradigastat, a novel diacylglycerol acyltransferase‐1 inhibitor, has activity in common metabolic diseases associated with abnormal accumulation of…”
Get full text

Pharmacokinetic and pharmacodynamic drug-drug interaction assessment between pradigastat and digoxin or warfarin by Yan, Jing-He, Meyers, Dan, Lee, Zachary, Danis, Kate, Neelakantham, Srikanth, Majumdar, Tapan, Rebello, Sam, Sunkara, Gangadhar, Chen, Jin

“…Pradigastat, a novel diacylglycerol acyltransferase‐1 inhibitor, was evaluated for both pharmacokinetic (PK) and pharmacodynamic (PD) drug–drug interactions…”
Get full text

Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers by Erpenbeck, Veit J., Vets, Eva, Gheyle, Lien, Osuntokun, Wande, Larbig, Michael, Neelakantham, Srikanth, Sandham, David, Dubois, Gerald, Elbast, Walid, Goldsmith, Paul, Weiss, Markus

“…We evaluated the pharmacokinetics (PK), safety, and tolerability of a novel oral CRTh2 antagonist, fevipiprant (QAW039), in healthy subjects. Peak…”
Get full text

Effect of pradigastat, a diacylglycerol acyltransferase 1 inhibitor, on the pharmacokinetics of a combination oral contraceptive in healthy female subjects by Chen, Jin, Bhansali, Suraj, Neelakantham, Srikanth, Trusley, Craig, Majumdar, Tapan, Rebello, Sam, Sunkara, Gangadhar, Meyers, Charles

“…We evaluated the potential pharmacokinetic interaction between pradigastat, a potent and selective diacylglycerol acyltransferase 1 inhibitor, and Levora-28®,…”
Get full text

Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects by Gan, Lu, Jiang, Xuemin, Mendonza, Anisha, Swan, Therese, Reynolds, Christine, Nguyen, Joanne, Pal, Parasar, Neelakantham, Srikanth, Dahlke, Marion, Langenickel, Thomas, Rajman, Iris, Akahori, Mizuki, Zhou, Wei, Rebello, Sam, Sunkara, Gangadhar

“…LCZ696 is a novel angiotensin receptor neprilysin inhibitor in development for the treatment of cardiovascular diseases. Here, we assessed the potential for…”
Get full text

Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women by Sivasubramanian, Rama, Chakraborty, Abhijit, Rouzade-Dominguez, Marie-Laure, Neelakantham, Srikanth, Jakab, Annamaria, Mensinga, Tjeert, Legangneux, Eric, Woessner, Ralph, Ufer, Mike

“…To compare the pharmacokinetics (PKs) of a combination oral contraceptive (OC) when given alone or concomitantly with the selective metabotropic glutamate…”
Get full text

Effect of Pradigastat, a Diacylglycerol Acyltransferase 1 Inhibitor, on the QTcF Interval in Humans by Meyers, Charles D., Noe, Adele, Salunke, Atish, Movva, Aishwarya, Kulmatycki, Kenneth, Neelakantham, Srikanth, Crissey, Anne, Majumdar, Tapan, Chen, Jin

“…Pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor, has been studied in familial chylomicronemia syndrome. To evaluate the effects of…”
Get full text

Bioavailability of valsartan oral dosage forms by Sunkara, Gangadhar, Bende, Girish, Mendonza, Anisha E., Solar-Yohay, Susan, Biswal, Shibadas, Neelakantham, Srikanth, Wagner, Robert, Flarakos, Jimmy, Zhang, Yiming, Jarugula, Venkateswar

“…The oral bioavailability of valsartan from extemporaneous suspension and solution formulations were evaluated relative to tablet formulation in two separate…”
Get full text